Abstracts tagged "tapering"

Abstract Number: 0364 • ACR Convergence 2021
Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Routine Care – 2-year Clinical and MRI Outcomes and Predictors of Successful Tapering
Marie Wetterslev¹, Stylianos Georgiadis², Inge Juul Sørensen³, Susanne Juhl Pedersen², Sara Nysom Christiansen⁴, Merete Lund Hetland¹, Cecilie Heegaard Brahe², Mads Bakkegaard⁵, Anne Duer⁶, Mikael Boesen⁷, Kasper Kjærulf Gosvig⁸, Jakob Møllenbach Møller⁸, Niels Steen Krogh⁹, Bente Jensen⁵, Ole Rintek Madsen⁵, Jan Christensen⁵, Annette Hansen⁵, Jesper Nørregaard⁵, Henrik Røgind⁵ and Mikkel Ostergaard¹⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁶Department of Radiology, Rigshospitalet, Glostrup, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁸Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in clinical remission who tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to…
Abstract Number: 0819 • ACR Convergence 2021
A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Mohamed Tageldin¹, Malavikalakshmi Attur², Nicole Wilson¹, Rebecca Schorr³ and Tarun Sharma¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Drexel University School of Medicine, Philadelphia, PA, ³Highmark Health, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Patients with chronic RA remain…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 0929 • ACR Convergence 2021
Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
Marie Wetterslev¹, Stylianos Georgiadis², Sara Nysom Christiansen³, Susanne Juhl Pedersen², Inge Juul Sørensen⁴, Merete Lund Hetland¹, Anne Duer⁵, Mikael Boesen⁶, Kasper Kjærulf Gosvig⁷, Jakob Møllenbach Møller⁷, Mads Bakkegaard⁸, Cecilie Heegaard Brahe², Niels Steen Krogh⁹, Bente Jensen⁸, Ole Rintek Madsen⁸, Jan Christensen⁸, Annette Hansen⁸, Jesper Nørregaard⁸, Henrik Røgind⁸ and Mikkel Ostergaard¹⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Department of Radiology, Rigshospitalet, Glostrup, Copenhagen, Denmark, ⁶Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to a clinical guideline and were followed for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].